Home / Recalls / Rubicon Research Private Limited / D-0659-2024

D-0659-2024 Class III Ongoing

Recalled by Rubicon Research Private Limited — Ambarnath

FDA drug recall D-0659-2024 was initiated by Rubicon Research Private Limited on Aug 24, 2024 and is designated Class III. Reason for recall: Discoloration The recall status is ongoing. Affected quantity: 3,984 bottles.

Recall details

Product Type: Drugs
Report Date: Sep 25, 2024
Initiation Date: Aug 24, 2024
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 3,984 bottles

Product description

AcetaZOLAMIDE Tablets, USP, 125 mg, 100 count bottled, Rx Only, Distributed by: Advagen Pharma Limited, Plainsboro, NJ, Manufactured by Rubicon Research Private Limited, Thane, India NDC 72888-047-01

Reason for recall

Discoloration

Distribution pattern

Nationwide in the US

Code information

Lot # 30575HF1, exp. date, Nov 2026 NDC# 72888-047-01

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-0659-2024
openFDA file date: Nov 10, 2026
Loaded by RegDataLab: Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.